CP. we both say DISRUPTIVE, so a $5 SP? Yep, $5 now, see below
However, in the context of your first write-up, the quote of 100 to 200$ billion testing business, could have been misconstrued as applying to cancer related tests, my bad.
but my point was No Way, as the part cannot be as big, or a huge sector of, the whole $107billion total US cancer treatment costs.
As we have "simple and quick" test routines with exosome, the cost should be relatively low and that points to a relatively low pricing -- never mind the benefit. Also such pricing and our straight forward applications would point to a rapid market penetration in the cancer treatment sector. Say exosomes USA at $4B?
As to annual routine tests, I mentioned my take for the USA in responding to shipbuilder.
Now, Peregrine should announce seeking a spin-off into a joint venture for the exosome test business, with an IPO (10% of shares) and stock for PPHM holders and the joint venturer. Just announcing an IB name for the partner search and deal structuring, would put our PPS way above $1 instantly.
best,
N
Market Data 
Markets 
